Nettet5. jul. 2024 · CAMBRIDGE, Mass. - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced the closing of an underwritten public offering of 4,758,620 shares of its common stock, including the … Nettet26. jun. 2024 · Intellia is enrolling adults between 18 to 80 years old with inherited ATTR and symptoms of nerve damage. Some, not all, have heart damage. They'll be tracked for two years. The results published in NEJM, which are also being presented at a medical conference on Saturday, are from three patients who received a low dose and three …
Intellia Therapeutics Announces Pricing of Public Offering of …
Nettet8. mar. 2024 · As of December 31, 2024, Intellia Therapeutics had a cash position of $1.3 billion - an increase from the previous year. This shows that the company has a stable financial platform to back its... Nettet10. apr. 2024 · Sangharsh Lohakare. In a national first, the Food and Drug Administration has given Intellia Therapeutics the go-ahead to begin testing a drug that uses CRISPR gene editing in vivo.. In biology ... infj woman personality
Intellia Therapeutics Announces Closing of $201 Million Public …
Nettet1. des. 2024 · CAMBRIDGE, Mass., Nov. 30, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company … Nettet1. des. 2024 · CAMBRIDGE, Mass., Nov. 30, 2024 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced today the pricing of an underwritten public offering of … Nettet28. jun. 2024 · Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the... infj woman infp man